- Home
- SDST vs JSPR Comparison
SDST vs JSPR Comparison
Compare SDST & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDST | JSPR |
|---|---|---|
| Founded | 2022 | 2018 |
| Country | United States | United States |
| Employees | 10 | 22 |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5M | 14.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SDST | JSPR |
|---|---|---|
| Price | $1.68 | $0.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 83.1K | ★ 451.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.32 |
| 52 Week High | $7.67 | $3.84 |
Technical Indicators
Market Signals| Indicator | SDST | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 41.61 | 48.62 |
| Support Level | N/A | $0.42 |
| Resistance Level | $2.69 | $0.60 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 32.22 | 70.13 |
Price Performance
Historical ComparisonAbout SDST Stardust Power Inc.
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.